Ergomed plc Result of AGM (3958I)
17 June 2017 - 2:44AM
UK Regulatory
TIDMERGO
RNS Number : 3958I
Ergomed plc
16 June 2017
PRESS RELEASE
FOR IMMEDIATE RELEASE
Results of 2017 Annual General Meeting
London, UK -16 June 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or
'the Company'), a company dedicated to the provision of specialised
services to the pharmaceutical industry and the development of new
drugs, today announces that all resolutions put to shareholders
were duly passed at its Annual General Meeting held earlier
today.
Resolutions 1 to 5 were passed on a show of hands.
Details of proxy results were as follows:
Resolution Votes for Votes against Abstentions
number
----------- ---------- -------------- ------------
1 7,173,627 152,834 Nil
----------- ---------- -------------- ------------
2 7,325,794 Nil 667
----------- ---------- -------------- ------------
3 7,325,794 Nil 667
----------- ---------- -------------- ------------
4 7,325,794 Nil 667
----------- ---------- -------------- ------------
5 7,315,839 Nil 10,622
----------- ---------- -------------- ------------
Details of voting results for resolutions 6 and 7 (including
proxies) were as follows:
Resolution Votes for Votes against Abstentions
number
----------- ----------- -------------- ------------
6 24,118,915 4,235,625 13,622
----------- ----------- -------------- ------------
7 24,118,915 4,235,625 13,622
----------- ----------- -------------- ------------
The full text of all resolutions can be found in the Notice of
Annual General Meeting on the Company's website
www.ergomedplc.com
ENDS
Enquiries:
Ergomed plc Tel: +44 (0)
1483 503205
Miroslav Reljanovic (Chief Executive
Officer)
Stephen Stamp (Chief Financial
Officer)
Numis Securities Limited Tel: +44 (0)
20 7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0)
20 7496 3000
Alex Price (Joint Broker)
Consilium Strategic Communications Tel: +44 (0)
- for UK enquiries 20 3709 5700
Chris Gardner / Mary-Jane ergomed@consilium-comms.com
Elliott / Ivar Milligan
MC-Services - for Continental Tel: +49 211
European enquiries 5292 5222
Anne Hennecke
About Ergomed
Ergomed plc is a profitable UK-based business providing drug
development services to the pharmaceutical industry and has a
growing portfolio of co-development partnerships. It operates in
over 50 countries.
Ergomed provides clinical development, trial management and
pharmacovigilance services to over 100 clients ranging from top 10
pharmaceutical companies to small and mid-sized drug development
companies. Ergomed successfully manages clinical development from
Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular
expertise in oncology, neurology and immunology and the development
of orphan drugs. Ergomed believes its approach to clinical trials
is differentiated from that of other providers by its innovative
Study Site Management model and the use of Study Physician Teams,
resulting in a close relationship between Ergomed and the
physicians involved in clinical trials.
As well as providing high quality clinical development services,
Ergomed is building a portfolio of co-development partnerships with
pharma and biotech companies which share the risks and rewards of
drug development. Ergomed leverages its expertise and services in
return for carried interest in the drugs under development. Lastly,
Ergomed acquired a pipeline of proprietary development products for
the treatment of surgical bleeding. For further information, visit:
http://ergomedplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGLLFSRRFIRLID
(END) Dow Jones Newswires
June 16, 2017 12:44 ET (16:44 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024
